Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 F276C |
| Therapy | Pazopanib |
| Indication/Tumor Type | intrahepatic cholangiocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 F276C | intrahepatic cholangiocarcinoma | predicted - sensitive | Pazopanib | Case Reports/Case Series | Actionable | In a clinical case study, Votrient (pazopanib) treatment resulted in a partial response that continued for 11 months after starting treatment in a patient with intrahepatic cholangiocarcinoma harboring FGFR2 F276C (PMID: 34480077). | 34480077 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (34480077) | Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma. | Full reference... |